«s. 43 (1)(c) provided flexibility in LOE benefits to older workers while avoiding the problem of predicting when a worker would have retired. (slaw.ca)
In an April 3, 2018 research note, analyst Douglas Loe reported that Echelon Wealth Partners again designated Immunovaccine Inc. (IMV: TSX; IMMVF: OTCQX) Top Pick in Q2 / 18, marking the third consecutive quarter it has done so. (thelifesciencesreport.com)
Loe said interim tumor and immunological response data are likely in FY H2 / 18 at the earliest. (thelifesciencesreport.com)